US Nucleic Acid Therapeutics Market Research Report—Forecast till 2032

US Nucleic Acid Therapeutics Market Research Report Information By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others), By Application (Monogenetic Disorders and Multi-genetic Disorders), By End User (Hospitals and Clinics and Academic and Research Institutes) –Market Forecast Till 2032

ID: MRFR/HC/11123-HCR | 128 Pages | Author: Rahul Gotadki | March 2024         

US Nucleic Acid Therapeutics Market Overview


The nucleic acid therapeutics market industry is projected to grow from USD Significant by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2023 - 2032). The development of biological products, DNA therapies, and the growth of the pharmaceutical and healthcare industries are all significant market drivers that have propelled the nucleic acid therapeutics market upward.


US Nucleic Acid Therapeutics Market Overview


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Nucleic Acid Therapeutics Market Trends



  • Rising prevalence of genetic diseases is driving the market growth


The demand for nucleic acid-based therapeutics—which correct aberrant gene expression to treat diseases like cancer, sickle cell anemia, cystic fibrosis, Duchenne muscular dystrophy, thalassemia, and others—is primarily driven by the rising prevalence of genetic diseases. For instance, data from the Cystic Fibrosis Foundation released in July 2022 states that 40,000 adults and children in the US have cystic fibrosis (CF). Thus, the market is anticipated to benefit from the high prevalence of cystic fibrosis in the US population. Furthermore, novel therapeutic pharmaceuticals are becoming more readily available in the market as a result of companies' increasing focus on partnerships, collaborations, new product launches, and other initiatives. This might potentially drive the market's expansion. For example, in an effort to improve the treatment efficacy of antisense oligonucleotides in Charcot-Marie-Tooth disease, the CMT Research Foundation and Nanite Inc. joined in February 2023.


Governments, drug manufacturers, and biotechnology businesses are investing more money in nucleic acid-based therapies research and development. This monetary assistance has stimulated creativity and expedited the introduction of novel treatments to the market. Additionally, regulatory bodies like the Food and Drug Administration (FDA) in the United States have streamlined the clearance process for nucleic acid-based medicines and created clear criteria. The expansion of the market has been fueled by these regulatory frameworks, which have incentivized companies to spend in the development of these therapies. Moreover, in the market for nucleic acid therapeutics, cooperation between pharmaceutical corporations, biotechnology businesses, and academic institutions has increased. Partnerships speed up the creation and marketing of new products by facilitating the sharing of information, the pooling of resources, and technological improvements. Thus, driving the nucleic acid therapeutics market revenue.


Nucleic Acid Therapeutics Market Segment Insights


Nucleic Acid Therapeutics Product Insights


The US Nucleic Acid Therapeutics market segmentation, based on product includes Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others. The anti-sense oligonucleotides (ASOs) segment dominated the market mostly. Antisense oligonucleotides (ASOs) are single-stranded, short RNA or DNA molecules that can attach themselves to particular messenger RNA (mRNA) sequences and cause the targeted mRNA to either degrade or not translate into a protein. This characteristic renders ASOs a potentially effective treatment approach for a range of ailments, encompassing genetic abnormalities, infectious diseases, and cancer.


Nucleic Acid Therapeutics Application Insights


The US Nucleic Acid Therapeutics market segmentation, based on application, includes Monogenetic Disorders and Multi-genetic Disorders. The monogenetic disorders category generated the most income because most disorders that are treated with nucleic acid therapies are genetic and quite common. The primary driver of the nucleic acid therapeutics market expansion is the introduction of recently developed and authorized treatments for single gene defects by leading industry players. The top players in the field are concentrating on creating novel approaches to address issues with stability, off-targets, and gene quality in multi-genetic illnesses.


Figure 1: US Nucleic Acid Therapeutics Market, by Application, 2022 & 2032 (USD Billion)


US Nucleic Acid Therapeutics Market, by Application, 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Nucleic Acid Therapeutics End User Insights


The US Nucleic Acid Therapeutics market segmentation, based on end user, includes Hospitals and Clinics and Academic and Research Institutes. The hospitals and clinics category generated the most income. As more treatments and immunizations are used to address a wide range of chronic illnesses, the market for customized pharmaceuticals is growing. This market sector is also being driven by the increasing number of people visiting hospitals and clinics.


Nucleic Acid Therapeutics Regional Insights


The US nucleic acid therapeutics market area will grow at a significant rate because new nucleic acid treatments are becoming more and more approved, and because nucleic acid extraction technology is readily available. The nation's market growth has reached its pinnacle and is anticipated to stay there for the duration of the projection period due to the availability of all positive elements. Additionally, the need for nucleic acid-based therapeutics is rising due to the increasing frequency of autoimmune illnesses in the population, which could boost the market's growth. For example, in June 2022 the Autoimmune Association reported that over 31 million Americans suffer from autoimmune disorders, which are classified as 80–150 distinct chronic conditions. This demonstrates how common autoimmune diseases are in the intended audience.


Nucleic Acid Therapeutics Key Market Players & Competitive Insights


Leading market players are investing heavily in research and development in order to expand their product lines, which will help the nucleic acid therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, nucleic acid therapeutics industry must offer cost-effective items.


Key Companies in the nucleic acid therapeutics market include



  • Benitec Biopharma

  • Sarpeta Therapeutics

  • NOVARTIS AG.

  • Agilent Technologies

  • Protagonist Therapeutics

  • Qaigen NV

  • Genzyme Sanofi

  • Thermo Fisher Scientific

  • Copernicus

  • Arbutus Biopharma

  • Merck KGaA

  • Silence Therapeutics


Nucleic Acid Therapeutics Market Segmentation


Nucleic Acid Therapeutics Products Outlook



  • Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers

  • RNA interference [RNAi] and short interfering RNAs [siRNAs]

  • Others


Nucleic Acid Therapeutics Application Outlook



  • Monogenetic disorders

  • Multi-genetic disorders


Nucleic Acid Therapeutics End User Outlook



  • Hospitals and Clinics

  • Academic and Research Institutes

Report Scope:

Report Attribute/Metric Details
Market Size 2022 USD XX Billion
Market Size 2023 USD XX Billion
Market Size 2032 USD XX Billion
Compound Annual Growth Rate (CAGR) 10.10% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, Application, End User, and Region
Countries Covered US
Key Companies Profiled Benitec Biopharma, Sarpeta Therapeutics, NOVARTIS AG., Agilent Technologies, Protagonist Therapeutics, Qaigen NV, Genzyme Sanofi, Thermo Fisher Scientific, Copernicus, Arbutus Biopharma, Merck KGaA, and Silence Therapeutics
Key Market Opportunities ·       Quick Transition of the Pharmaceutical Sector to Novel Biologics
Key Market Dynamics ·       Increased Frequency of Genetic Disorders ·       Increasing Healthcare Sector Investments




Frequently Asked Questions (FAQ) :

The US Nucleic Acid Therapeutics market size was valued at USD Significant in 2022.

The market is projected to grow at a CAGR of 10.10% during the forecast period, 2023-2032.

The key players in the market are Benitec Biopharma, Sarpeta Therapeutics, NOVARTIS AG., Agilent Technologies, Protagonist Therapeutics, Qaigen NV, Genzyme Sanofi, Thermo Fisher Scientific, Copernicus, Arbutus Biopharma, Merck KGaA, and Silence Therapeutics.

The Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers category dominated the market in 2022.

The Hospitals and Clinics category had the largest share in the market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid